{"id":"W1940434397","doi":"10.1007/s00280-015-2852-2","title":"Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma","year":2015,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"ca_institutions":"Georgetown Hospital","funders":"Lombardi Comprehensive Cancer Center, Georgetown University; American Cancer Society","keywords":"Medicine; Sorafenib; Tolerability; Internal medicine; Clinical endpoint; Nausea; Hepatocellular carcinoma; Temozolomide; Phases of clinical research; Regimen; Veliparib; Gastroenterology; Surgery; Progressive disease; Vomiting; Oncology; Clinical trial; Adverse effect; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001192382,0.001133157,0.002703176,0.0003631074,0.0002401947,0.0006135359,0.0007127662,0.0006425091,0.002399671],"category_scores_gemma":[0.0006802097,0.0004062124,0.0006746427,0.0003814146,0.000566405,0.0004479967,0.0002794898,0.001918574,0.0005997996],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006954399,"about_ca_system_score_gemma":0.001287777,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006047492,"about_ca_topic_score_gemma":0.001588828,"domain_scores_codex":[0.999674,0.0001605508,0.0000234136,0.00004967762,0.00003459099,0.00005788686],"domain_scores_gemma":[0.9994553,0.00008888829,0.0001098164,0.00003635066,0.00003219753,0.0002775001],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6186982,0.0769372,0.01334121,0.001580503,0.002294203,0.0007240219,0.0003539794,0.006185274,0.1119481,0.000277866,0.004448225,0.1632112],"study_design_scores_gemma":[0.5832707,0.3895271,0.0122845,0.00004124007,0.0005271273,0.0007078879,0.00005277055,0.002700565,0.007901758,0.0001094692,0.002848229,0.00002861325],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950162,0.001947238,0.0004655288,0.0002185057,0.00006009531,0.001201376,0.0003393352,0.00006683413,0.0006849293],"genre_scores_gemma":[0.9934243,0.001264377,0.001379766,0.000281766,0.0001149898,0.001392572,0.001023991,0.00001857605,0.001099572],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002703176,"threshold_uncertainty_score":0.008027732,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09353586075040868,"score_gpt":0.3560939212492875,"score_spread":0.2625580604988789,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}